

Supplemental table 1. Distribution of ETS and DoR according to clinico-pathological and treatment characteristics in patients with clinical benefit.

Characteristics	Early tumor shrinkage (%)		Depth of response (%)	
	Median (IQR)	P	Median (IQR)	P
Sex		0.078		0.141
Female (N=63)	-25 (-39 to -2)		-53 (-80 to -28)	
Male (N=69)	-15 (-32 to 7)		-44 (-76 to -17)	
Age (years)		0.187		0.018
<70 (N=92)	-16 (-31 to 0)		-43 (-70 to -19)	
≥70 (N=40)	-25 (-38 to 0)		-63 (-100 to -33)	
ECOG PS		0.628		0.599
0 (N=90)	-22 (-35 to 0)		-50 (-76 to -26)	
≥1 (N=42)	-16 (-34 to 0)		-47 (-77 to -20)	
Primary tumor sidedness		0.651		0.476
Left (N=34)	-17 (-35 to 7)		-46 (-75 to -16)	
Right (N=98)	-20 (-35 to 0)		-50 (-78 to -26)	
RAS and BRAF mutational status		0.393		0.097
All wild-type (N=50)	-21 (-40 to 3)		-49 (-76 to -20)	
RAS mutated (N=38)	-13 (-31 to 2)		-45 (-58 to -16)	
BRAF mutated (N=44)	-23 (-38 to 0)		-63 (-100 to -33)	
Synchronous metastases		0.483		0.171
No (N=61)	-14 (-35 to 3)		-44 (-70 to -22)	
Yes (N=71)	-20 (-34 to -2)		-51 (-86 to -24)	
Liver metastases		0.930		0.893
No (N=84)	-18 (-35 to 0)		-46 (-83 to -22)	
Yes (N=48)	-21 (-33 to -3)		-51 (-74 to -23)	
Lung metastases		0.164		0.023
No (N=102)	-22 (-36 to 0)		-54 (-84 to -27)	
Yes (N=30)	-9 (-32 to 5)		-37 (-54 to -7)	
Lymph nodal metastases		0.025		0.061
No (N=42)	-5 (-35 to 7)		-35 (-72 to -11)	
Yes (N=90)	-23 (-35 to -4)		-54 (-83 to -30)	
Peritoneal metastases		0.300		0.971
No (N=87)	-23 (-36 to 0)		-48 (-76 to -23)	
Yes (N=45)	-13 (-32 to 0)		-49 (-84 to -22)	
Bone metastases		0.922		0.874
No (N=126)	-19 (-35 to 0)		-49 (-77 to -23)	
Yes (N=6)	-24 (-31 to -4)		-46 (-78 to -22)	
Number of metastatic sites		0.772		0.155
1 (N=56)	-22 (-36 to 0)		-54 (-100 to -27)	
≥2 (N=76)	-19 (-33 to 0)		-48 (-71 to -22)	
Prior systemic treatment for metastatic disease		0.106		0.051
No (N=33)	-25 (-38 to 0)		-61 (-100 to -36)	

Yes (N=99)	-14 (-32 to 0)		-45 (-75 to -20)	
Time from metastatic condition to ICI treatment start		0.141		0.034
<18 months (N=91)	-23 (-38 to 0)		-54 (-83 to -27)	
≥ 18 months (N=41)	-13 (-27 to 3.4)		-38 (-58 to -8)	
ICI regimen		0.181		<0.001
Anti-PD-1 (N=84)	-14 (-33 to 2)		-38 (-66 to -19)	
Anti-CTLA-4 + anti-PD-1 (N=48)	-24 (-37 to -4)		-62 (-100 to -43)	